GLP-1 Availability and Pricing: 2026 Update
The current state of GLP-1 supply, insurance coverage, and pricing in 2026 — and what it means for patients.
Read this first
Availability and pricing change by state and month. This is general education, not a quote or medical advice. Compounded GLP-1s are not FDA-approved, and since the 2025 shortage delistings they can only be dispensed in narrow, patient-specific circumstances.
The 2026 access picture is very different from 2023. The shortages ended, and with them the legal pathway that let compounded semaglutide and tirzepatide fill the gap. Access now runs through the approved products and what your insurance will do about them.
Is there still a GLP-1 shortage in 2026?
Wegovy® and Zepbound® remain in high demand, but manufacturers expanded capacity enough for the FDA to formally resolve both shortages — tirzepatide in December 2024 and semaglutide in February 2025. Those declarations are what changed the compounding picture, because the main exemption compounders relied on applies only while a drug is in shortage.
Can you still get compounded semaglutide or tirzepatide?
Not the way they were. Once the shortages were resolved, the FDA set deadlines to stop compounding under that exemption: tirzepatide by February 19, 2025 for 503A pharmacies and March 19 for 503B facilities; semaglutide by April 22 and May 22 respectively. Those dates have passed.
What remains is narrower. Under section 503A a licensed pharmacy can compound a patient-specific preparation against a prescription where the prescriber documents a clinically significant difference from the approved product for that patient — a documented allergy to an inactive ingredient, for example. What is not permitted is compounding what amounts to a copy of the approved drug, routinely, for a general population. In April 2026 the FDA went further and proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulk substances list altogether.
Does insurance cover GLP-1s in 2026?
- Coverage varies by plan; prior auth and step therapy are common.
- Manufacturer savings cards can cut brand cost for commercial-insurance holders.
- Compounded pricing was typically $200–$500/mo when it was widely offered; it is no longer a routine option and should not be assumed as a fallback.
What does the 2026 supply picture mean for patients?
If you are evaluating options in 2026, the questions are: is this the approved product or a compounded one, what is the total monthly cost, and — if compounded — what clinical reason has the prescriber documented for not using the approved drug. Ask directly, and expect a specific answer.
Bottom line
The defining fact of 2026 access is that the shortages ended and the compounding pathway narrowed sharply. Branded supply has improved; insurance coverage is now the main barrier for most people. If someone offers you a compounded GLP-1, ask what documented clinical basis puts it inside the remaining exception. This is education, not a quote or medical advice.
Want this handled for you?
LunaRx — clinician-led GLP-1 care with a plan to come off
LunaRx connects you with a licensed clinician for an online evaluation. Depending on your state that is a live or a store-and-forward visit. If the clinician determines a GLP-1 is appropriate for you, a licensed pharmacy dispenses it — with a plan to come off when you’re ready. The prescribing decision is the clinician’s alone, and approval is not guaranteed.
Sources
Primary sources for the claims in this article. Trial results are reported as published; prescribing information is the authoritative reference for dosing and safety.
- 1.FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
U.S. Food and Drug Administration · 2025
Shortages resolved (tirzepatide December 2024, semaglutide February 2025) and the compounding enforcement deadlines that followed.
- 2.Declaratory Order: Resolution of the Shortage of Tirzepatide Injection
U.S. Food and Drug Administration · 2024
FDA's formal determination that the tirzepatide injection shortage was resolved.
- 3.Declaratory Order: Resolution of the Shortage of Semaglutide Injection
U.S. Food and Drug Administration · 2025
FDA's formal determination that the semaglutide injection shortage was resolved.
- 4.FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List
U.S. Food and Drug Administration · 2026
April 2026 proposal to exclude these molecules from the 503B bulk drug substances list.
Get the weekly research update
New trials, FDA moves, and pricing shifts — one plain-English email a week. No spam.
Unsubscribe anytime. Read our privacy policy.